Latest stories on BRTX
BioRestorative Marks Major Milestone: BRTX-100 Phase 2 Dosing Complete, Eyes Topline Data in 2027
MarketChameleon67 · bullishproduct/pr
BRTX-100 Phase 2 Dosing Complete: BioRestorative Advances Regenerative Spine Therapy with FDA Fast Track Status
MarketChameleon67 · bullishproduct/pr
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
PR Newswire58 · neutralm&a